Abortion Research Today is a free monthly online journal that collates and summarizes the latest research about Abortion, including details on abortion pill, procedure, facts, information. | ||||||||
|
Factor V Leiden mutation in relation to fecundity and miscarriage in women with venous thrombosis.van Dunné FM, Doggen CJ, Heemskerk M, Rosendaal FR, Helmerhorst FM Department of Obstetrics, Gynaecology and Reproductive Medicine, Leiden University Medical Center, P.O.Box 9600, 2300 RC Leiden, The Netherlands. BACKGROUND: Factor V Leiden mutation (Arg506Gln) increases the likelihood of venous thrombosis; it may also have a positive effect through facilitation of embryo implantation. This may manifest itself as a reduced time to pregnancy (increased fecundity) and fewer miscarriages in the first trimester. METHODS: From March 1999 onwards, consecutive patients with a first venous thrombosis (VT) were recruited. The first 115 female VT patients with factor V Leiden and 230 age-matched female VT patients without factor V Leiden were included. All patients, unaware of their genotype, received a structured questionnaire. RESULTS: Of the 297 (86%) women who returned the questionnaire, 220 had been pregnant at least once. Time to first pregnancy was unaffected by carrier status: 58% factor V Leiden carriers reported a pregnancy within 3 months compared to 54% non-carriers. The miscarriage proportion was 14%, similar in both groups. First trimester miscarriage was less frequent among carriers (46%) than among non-carriers (95%) (relative risk 0.5, 95% confidence interval 0.3-0.9). CONCLUSIONS: Factor V Leiden mutation may support embryo implantation, as factor V Leiden carriers had fewer miscarriages in the first trimester with a similar overall miscarriage rate. Miscarriage of embryos with poor viability may be postponed until the second trimester in factor V Leiden carriers. Fecundity was not influenced by factor V Leiden status. Published 18 February 2005 in Hum Reprod, 20(3): 802-6.
© 2004-2008 Abortion Research Today. All Rights Reserved. |
| ||||||